> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Group Backs Circulating Tumor DNA as Early Endpoint
- URL: https://www.fdaweb.com/group-backs-circulating-tumor-dna-as-early-endpoint/
- Published: 2026-08-25T12:00:00.000Z
- Updated: 2026-09-14T12:05:48.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5161674

Friends of Cancer Research says it recently published two manuscripts supporting the use of circulating tumor DNA (ctDNA) as an early endpoint for regulatory decision-making. In a [media release](https://api.neonemails.com/emails/content/J9neaTFoaoDInyAG3e7o2U2MT2HKfCk9jlEbuTBAtEE=?ref=fdaweb.com) (contains links to the articles), the advocacy group says the manuscripts “show that on-treatment reductions in ctDNA levels are associated with improved overall survival and/or progression-free survival.”

The release says the publications highlight the robustness of ctDNA dynamics as a predictive biomarker across solid tumors and treatment modalities and support the potential use of on-treatment ctDNA reductions as an early endpoint in clinical trials.